Abstract
Thrombosis is the pathological face of the hemostatic process, and is still the major cause of death in the Western society. Many different components have been identified that contribute to the thrombotic occlusion of the vasculature and several therapeutic approaches have been developed to treat this severe clinical complication. In the last several years, a number of new agents have been under (pre)clinical investigation that are targeting von Willebrand factor (VWF), a protein that nicely exemplifies the thin line between the normal hemostatic process and an overly active system that gives rise to thrombotic events. Indeed, several epidemiological studies have found that increased plasma levels of VWF are associated with an increased risk for cardiovascular complications. VWF is a multimeric protein that is pertinent to the recruitment of platelets to the growing thrombus. VWF and platelets circulate together without interacting under normal conditions, and should combine into a thrombus selectively when necessary. This delicate process is highly regulated by various endothelial- and plasma proteins as well as by changes in shear stress. In the present review, an update is provided about our current knowledge on VWF as a risk factor, mediator and pharmacological target in association with thrombosis.
Keywords: Von Willebrand factor, thrombosis, risk factor, platelets, antithrombotic agents.
Current Vascular Pharmacology
Title:Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target
Volume: 11 Issue: 4
Author(s): Peter J. Lenting, Cecile V. Denis and Nikolett Wohner
Affiliation:
Keywords: Von Willebrand factor, thrombosis, risk factor, platelets, antithrombotic agents.
Abstract: Thrombosis is the pathological face of the hemostatic process, and is still the major cause of death in the Western society. Many different components have been identified that contribute to the thrombotic occlusion of the vasculature and several therapeutic approaches have been developed to treat this severe clinical complication. In the last several years, a number of new agents have been under (pre)clinical investigation that are targeting von Willebrand factor (VWF), a protein that nicely exemplifies the thin line between the normal hemostatic process and an overly active system that gives rise to thrombotic events. Indeed, several epidemiological studies have found that increased plasma levels of VWF are associated with an increased risk for cardiovascular complications. VWF is a multimeric protein that is pertinent to the recruitment of platelets to the growing thrombus. VWF and platelets circulate together without interacting under normal conditions, and should combine into a thrombus selectively when necessary. This delicate process is highly regulated by various endothelial- and plasma proteins as well as by changes in shear stress. In the present review, an update is provided about our current knowledge on VWF as a risk factor, mediator and pharmacological target in association with thrombosis.
Export Options
About this article
Cite this article as:
Lenting J. Peter, Denis V. Cecile and Wohner Nikolett, Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040008
DOI https://dx.doi.org/10.2174/1570161111311040008 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [ Hot Topic:The Medicinal Chemistry of New Agents to Treat Diabetes and Obesity (Guest Editor: Jie-Fei Cheng)]
Current Topics in Medicinal Chemistry Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Impact of Nutrients on the Functioning of Intestinal Goblet Cells: Health and Therapeutic Perspectives
Current Nutrition & Food Science Premature Ageing Prevention: Limitations and Perspectives of Pharmacological Interventions
Current Drug Targets Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Anti-apoptotic Serpins as Therapeutics in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Angiogenesis in Ischemic Tissues by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects
Current Stem Cell Research & Therapy Metabolic Syndrome Components in Murine Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews Development of Functional Dark Chocolate by Incorporating Flaxseed (Linum usitatissimum) Oil and Honey with Improved Organoleptic and Textural Attributes
Current Nutrition & Food Science Alterations in the Vascular Reactivity of Aorta in the Early and Late Phase of Adjuvant-Induced Arthritis in Rat
Vascular Disease Prevention (Discontinued) Guidelines and their Implementation: A Discussion Document Focused on the Best Approaches to Drive Improvement
Vascular Disease Prevention (Discontinued) Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Saturation of the Human Phenome
Current Genomics Effects of Low Doses of Polyunsaturated Fatty Acids on the Attention Deficit/Hyperactivity Disorder of Children: A Systematic Review
Current Neuropharmacology Lipoic Acid as a Potential Therapy for Chronic Diseases Associated with Oxidative Stress
Current Medicinal Chemistry Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials
CNS & Neurological Disorders - Drug Targets